Xalkori and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Xalkori (crizotinib).
Crizotinib Food/Lifestyle
Major Food Interaction
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of crizotinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Because crizotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
Food has no significant effect on the gastrointestinal absorption of crizotinib. According to the product labeling, a high-fat meal reduced crizotinib peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 14%.
MANAGEMENT: Patients treated with crizotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Crizotinib may be taken without regards to food.
References (1)
- (2011) "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group
Switch to consumer interaction data
Xalkori drug interactions
There are 819 drug interactions with Xalkori (crizotinib).
Xalkori disease interactions
There are 7 disease interactions with Xalkori (crizotinib) which include:
- bradycardia
- gastrointestinal perforation
- hepatic impairment
- ILD/pneumonitis
- QT prolongation
- renal impairment
- visual loss
Report options
More about Xalkori (crizotinib)
- Xalkori consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
